Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin

Garnet L. Anderson, Rowan T. Chlebowski, Jacques E. Rossouw, Rebecca J. Rodabough, Anne McTiernan, Karen L. Margolis, Anita Aggerwal, J. David Curb, Susan L. Hendrix, F. Allan Hubbell, Jamardan Khandekar, Dorothy S. Lane, Norman Lasser, Ana Maria Lopez, Jo Nell Potter, Cheryl Ritenbaugh

Research output: Contribution to journalArticlepeer-review

206 Scopus citations


Objectives: To assess the extent to which prior hormone therapy modifies the breast cancer risk found with estrogen plus progestin (E + P) in the Women's Health Initiative (WHI) randomized trial. Methods: Subgroup analyses of prior hormone use on invasive breast cancer incidence in 16,608 postmenopausal women in the WHI randomized trial of E + P over an average 5.6 years of follow-up. Results: Small but statistically significant differences were found between prior HT users and non-users for most breast cancer risk factors but Gail risk scores were similar. Duration of E + P use within the trial (mean 4.4 years, S.D. 2.0) did not vary by prior use. Among 4311 prior users, the adjusted hazard ratio (HR) for E + P versus placebo was 1.96 (95% confidence interval [CI]: 1.17-3.27), significantly different (p = 0.03) from that among 12,297 never users (HR 1.02; 95% CI: 0.77-1.36). The interaction between study arm and follow-up time was significant overall (p = 0.01) and among never users (p = 0.02) but not among prior users (p = 0.10). The cumulative incidence over time for the E + P and placebo groups appeared to cross after about 3 years in prior users, and after about 5 years in women with no prior use. No interaction was found with duration (p = 0.08) or recency of prior use (p = 0.17). Prior hormone use significantly increased the E + P hazard ratio for larger, more advanced tumors. Conclusion: A safe interval for combined hormone use could not be reliably defined with these data. However, the significant increase in breast cancer risk in the trial overall after only 5.6 years of follow-up, initially concentrated in women with prior hormone exposure, but with increasing risk over time in women without prior exposure, suggests that durations only slightly longer than those in the WHI trial are associated with increased risk of breast cancer. Longer-term exposure and follow-up data are needed.

Original languageEnglish (US)
Pages (from-to)103-115
Number of pages13
Issue number2
StatePublished - Sep 20 2006


  • Breast neoplasms
  • Estrogen
  • Progestin
  • Randomized trials
  • Subgroup analyses

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • Obstetrics and Gynecology


Dive into the research topics of 'Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin'. Together they form a unique fingerprint.

Cite this